• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.16% Nasdaq Up0.06%

    VIVUS Inc. (VVUS)

    -NasdaqGS
    3.16 Down 0.01(0.41%) 9:30AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    VIVUS Inc.
    351 East Evelyn Avenue
    Mountain View, CA 94041
    United States - Map
    Phone: 650-934-5200
    Website: http://www.vivus.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:98

    Business Summary 

    VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on VIVUS Inc.

    Corporate Governance 
    VIVUS Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 9; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Seth H. Z. Fischer , 57
    Chief Exec. Officer, Chief Commercial Officer and Director
    332.00KN/A
    Mr. Svai S. Sanford , 44
    Chief Financial Officer and Principal Accounting Officer
    342.00KN/A
    Mr. John L. Slebir Esq., 49
    Sr. VP of Bus. Devel. and Gen. Counsel
    511.00K0.00
    Mr. Guy P. Marsh , 60
    VP of U S Operations and Gen. Mang.
    463.00K0.00
    Dr. Wesley W. Day Ph.D., 51
    VP of Clinical Devel.
    541.00K0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders